CLAIMS

1. A combination comprising the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof, with cytarabine (B) for use in the treatment of acute myeloid leukaemias.

2. A combination comprising the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof, with cytarabine (B) for use in the treatment of chronic myeloid leukaemias.

3. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intravenous route.

4. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the oral route.

5. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intravenous route followed by the oral route.

6. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intraperitoneal route.

7. A combination for use according to anyone of the preceding claims, wherein cytarabine (B) is administered by the intravenous route.

8. A combination for use according to anyone of the preceding claims, wherein cytarabine (B) is administered by the intraperitoneal route

9. A combination for use according to claim 1, wherein compound (A) is administered by the intravenous route and cytarabine (B) is administered by the intravenous route.

10. A combination for use according to claim 1, wherein compound (A) is administered by the oral route and cytarabine (B) is administered by the intravenous route.

11. A combination for use according to claim 1, wherein compound (A) is administered by the intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.

12. A combination for use according to claim 2, wherein compound (A) is administered by the intravenous route and cytarabine (B) is administered by the intravenous route.

13. A combination for use according to claim 2, wherein compound (A) is administered by the oral route and cytarabine (B) is administered by the intravenous route.

14. A combination for use according to claim 2, wherein compound (A) is administered by the intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.

15. A combination for use according to claim 2, wherein compound (A) is administered by the intraperitoneal route followed by the oral route and cytarabine (B) is administered by the intraperitoneal route.

16. A combination for use according to anyone of the previous claims wherein compounds (A) and (B) are administered simultaneously, separately or sequentially.

17. A combination for use according to anyone of the preceding claims, where it is for treating AML or CML patients resistant to standard chemotherapy.

18. A combination for use according to anyone of the preceding claims, where it is for treating AML or CML in high risk cytogenetic patients.

19. A kit comprising :

- the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof,
- cytarabine (B)
- instructions for use in the treatment of acute myeloid leukaemias.

20. A kit comprising :

- the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof,
- cytarabine (B)
- instructions for use in the treatment of chronic myeloid leukaemias.

CLAIMS

1. A combination comprising the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof, with cytarabine (B) for use in the treatment of acute myeloid leukaemias wherein compound (A) is for administration by the intravenous route; andcytarabine (B) is for the administration by the intraperitoneal route.

2. A combination comprising the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a salt or a solvate thereof, with cytarabine (B) for use in the treatment of chronic myeloid leukaemias wherein:
   - compound (A) is for the administration by the intravenous route and cytarabine (B) is for the administration by the intraperitoneal route;
     or
   - compound (A) is for the administration by the intraperitoneal route and cytarabine (B) is for the administration by the intraperitoneal route.

3. A combination for use according to anyone of the previous claims wherein compounds (A) and (B) are for simultaneous, separate or sequential administration.

4. A combination for use according to anyone of the preceding claims, where it is for treating AML or CML patients resistant to standard chemotherapy.

5. A combination for use according to anyone of the preceding claims, where it is for treating AML or CML in high risk cytogenetic patients.